Clinical significance of anticardiolipin and anti-β2- glycoprotein I antibodies

International Archives of Allergy and Immunology

Volumn 135, Issue 2, 2004, Pages 148-153

  Obermoser, Gerlinde ^a   Bitterlich, Waltraud ^c   Kunz, Friedebert ^b   Sepp, Norbert T ^a  

^a Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Anti 2 glycoprotein I antibody; Anticardiolipin antibody; Antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; CONNECTIVE TISSUE DISEASE; FEMALE; HUMAN; MALE; MORBIDITY; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; THROMBOCYTOPENIA; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CHILD; CONNECTIVE TISSUE DISEASES; FEMALE; FETAL DEATH; GLYCOPROTEINS; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PREVALENCE; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOSIS;

EID: 5644244810     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080658     Document Type: Review

References (32)

1. Hughes GR: Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983;287:1088-1089.
2. Hughes GR: The antiphospholipid syndrome: Ten years on. Lancet 1993;342:341-344.
3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-1311.
4. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M; Euro-Phospholipid Project Group: Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-1027.
5. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547.
6. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-178.
7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4124.
8. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF: Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632.
9. Galli M: Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996;5:388-392.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
11. 2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus 1999;8:430-438.
12. 2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: Prevalence and diagnostic value for the antiphospholipid syndrome. J Rheumatol 2000;27:1437-1443.
13. 2- glycoprotein I: A potential marker for clinical features of antiphospholipid antibody syndrome in patients with systemic lupus erythematosus. J Rheumatol 1998;25:2131-2134.
14. 2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: A single center study and literature review. J Rheumatol 2000;27:2833-2837.
15. 2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: Clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998;25:667-674.
16. Teixido M, Font J, Reverter JC, Cervera R, Tassies D, Ingelmo M, Escolar G, Ordinas A: Anti-beta 2-glycoprotein I antibodies: A useful marker for the antiphospholipid syndrome. Br J Rheumatol 1997;36:113-116.
17. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR: Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-1243.
18. Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A: Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997;24:1710-1715.
19. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T: Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-1474.
20. 2-Glycoprotein 1 as a marker of antiphospholipid syndrome in women with recurrent pregnancy loss. Fertil Steril 2000;73:531-535.
21. Audrain MA, El-Kouri D, Hamidou MA, Mioche L, Ibara A, Langlois ML, Muller JY: Value of autoantibodies to beta(2)-glycoprotein 1 in the diagnosis of antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:550-553.
22. Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 2003;101:1827-1832.
23. Li Z, Krilis SA: Anti-beta(2)-glycoprotein I antibodies and the antiphospholipid syndrome. Autoimmun Rev 2003;2:229-234.
24. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL: Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother 2003;57:282-286.
25. Gharavi AE, Sammaritano LR, Wen J, Elkon KB: Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90:1105-1109.
26. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y: Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441-455.
27. Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG: Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992;67:499-502.
28. Galli M, Luciani D, Bertolini G, Barbui T: Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-2723.
29. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA: Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004;121:142-149.
30. 2GP-I) antibody assays as screening for antiphospholipid syndrome. Hum Antibodies 2003;12:57-62.
31. Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D: The antiphospholipid/cofactor syndromes: A primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996;101:472-481.
32. 2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome? Br J Haematol 2003;123:490-495.